Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.63 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663237 | 0.90 | HSD11B1 (0.64) | HSD11B1HSD11B2HDAC1NPC1RAB9A | |
| SCHEMBL1161043 | 0.81 | HSD11B1 (0.51) | HSD11B1HSD11B2NPC1RAB9AKMT2A | |
| SCHEMBL1161045 | 0.81 | HSD11B1 (0.51) | HSD11B1HSD11B2NPC1RAB9AKMT2A | |
| SCHEMBL9982588 | 0.81 | HSD11B1 (0.60) | HSD11B1HSD11B2HDAC1NPC1RAB9A | |
| SCHEMBL3663703 | 0.80 | HSD11B1 (0.59) | HSD11B1HSD11B2HDAC1NPC1RAB9A | |
| SCHEMBL28787535 | 0.79 | HSD11B1 (0.63) | HSD11B1HSD11B2HDAC1NPC1RAB9A | |
| SCHEMBL974109 | 0.78 | HSD11B1 (1.00) | HSD11B1HSD11B2 | |
| SCHEMBL3662764 | 0.78 | HSD11B1 (0.62) | HSD11B1HSD11B2NPC1RAB9AKMT2A | |
| SCHEMBL9947970 | 0.77 | HSD11B1 (0.87) | HSD11B1HSD11B2 | |
| SCHEMBL3665287 | 0.77 | HSD11B1 (0.49) | HSD11B1HSD11B2NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536173-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11-B-hydroxysteroid dehydrogenase type I | SANOFI (FR) | 2013-09-17 | — | — | US | disclosed |
| US-20120165337-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165337-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NR2C2, CBR3, NR0B2 | HSD11B1 1172/4885HSD11B2 991/4885HDAC1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.